Zeo ScientifiX joins three-way stem cell therapy partnership

Zeo ScientifiX ( (ZEOX) ) has provided an update.

On January 7, 2026, Zeo ScientifiX, Cytora Therapeutics and Made Scientific announced a three-way strategic partnership to manufacture and commercialize Cytora’s allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States. Under the collaboration, Cytora will license its hOMSC technology and continue clinical and regulatory development, Made Scientific will act as the exclusive U.S. GMP manufacturer from its New Jersey facilities, and Zeo will serve as the exclusive U.S. commercial partner, leveraging its market access, distribution and clinical site management infrastructure. The alliance will initially target commercialization in Florida under Senate Bill 1768, a stem cell access law that allows certain non-FDA-approved adult allogeneic stem cell therapies for wound care, pain and orthopedic conditions, with non-healing diabetic foot ulcers as the lead indication and plans to expand into broader wound, orthopedic and pain management categories that encompass millions of cases annually in the state. The partners also aim to support an FDA IND pathway for a Phase 2b clinical trial and future international submissions, building on Phase 1/2a data in diabetic foot ulcers in which Cytora’s hOMSC200 product showed a favorable safety profile and statistically significant superiority over placebo in wound reduction, including complete closure in long-standing ulcers, positioning the therapy and Zeo’s commercialization platform for a potentially meaningful role in the regenerative medicine treatment landscape for chronic wounds.

More about Zeo ScientifiX

Zeo ScientifiX, Inc. (OTCQB: ZEOX) is a Florida-based, clinical-stage biopharmaceutical company focused on research, clinical trials and manufacturing of biological products, with a portfolio of proprietary therapies derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell-derived exosomes, Wharton’s Jelly matrix, placental membrane tissues and amniotic fluid, as well as its autologous biologic Patient Pure X™, all produced in FDA-registered, cGMP-compliant facilities and aligned with Florida’s stem cell therapy law.

Average Trading Volume: 18,675

Technical Sentiment Signal: Strong Buy

Current Market Cap: $18.28M

For an in-depth examination of ZEOX stock, go to TipRanks’ Overview page.